Healthcare -
Medical - Diagnostics & Research - NASDAQ - US
$ 45.63
-5.8 %
$ 1.64 B
Market Cap
-0.77
P/E
1. INTRINSIC VALUE
Balance Sheet
GRAIL, Inc.
| Current Assets | 820 M |
| Cash & Short-Term Investments | 763 M |
| Receivables | 24.6 M |
| Other Current Assets | 31.8 M |
| Non-Current Assets | 2.16 B |
| Long-Term Investments | 0 |
| PP&E | 135 M |
| Other Non-Current Assets | 2.03 B |
| Current Liabilities | 76.9 M |
| Accounts Payable | 4.84 M |
| Short-Term Debt | 13.3 M |
| Other Current Liabilities | 58.8 M |
| Non-Current Liabilities | 403 M |
| Long-Term Debt | 54.9 M |
| Other Non-Current Liabilities | 348 M |
EFFICIENCY
Earnings Waterfall
GRAIL, Inc.
| Revenue | 126 M |
| Cost Of Revenue | 204 M |
| Gross Profit | -78 M |
| Operating Expenses | 2.25 B |
| Operating Income | -2.19 B |
| Other Expenses | -162 M |
| Net Income | -2.03 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
GRAIL, Inc.
| Net Income | -2.03 B |
| Depreciation & Amortization | 158 M |
| Capital Expenditures | -5.21 M |
| Stock-Based Compensation | 86.1 M |
| Change in Working Capital | -24.3 M |
| Others | 1.35 B |
| Free Cash Flow | -582 M |
Wall Street Analysts Price Targets
GRAIL, Inc.
Wall Street analysts predict an average 1-year price target for GRAL of $32 , with forecasts ranging from
a
low of
$32 to a high of $32 .
GRAL Lowest Price Target
Wall Street Target
32 USD
-29.87%
GRAL Average Price Target
Wall Street Target
32 USD
-29.87%
GRAL Highest Price Target
Wall Street Target
32 USD
-29.87%
4. DIVIDEND
ANALYSIS
GRAL does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
GRAIL, Inc.
Sold
0-3 MONTHS
6.63 M USD 3
3-6 MONTHS
360 K USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Grail Shares Jump on Promising Results for Galleri Study
Shares of Grail climbed after the company said the second study of its Galleri multi-cancer early detection test provided even more promising results than the first.
marketwatch.com
- 1 week ago
GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study
Cancer Detection and Positive Predictive Value Substantially Higher Than the Previously Published PATHFINDER Study MENLO PARK, Calif. , June 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced positive top-line performance and safety results from the pre-specified analysis of the first 25,578 participants in GRAIL's registrational PATHFINDER 2 study.
prnewswire.com
- 1 week ago
3 Medical Technology Stocks Outperforming in 2025
As the broader market stages a sharp rebound from its April lows, several sectors, industries, and stocks have quietly emerged as leaders. Among them, the medical technology industry, known for its innovation and growth potential, has stood out.
marketbeat.com
- 2 weeks ago
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif. , May 30, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 77,350 shares of GRAIL's common stock to 38 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.
prnewswire.com
- 4 weeks ago
GRAIL to Present at Jefferies Global Healthcare Conference 2025
MENLO PARK, Calif. , May 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Jefferies Global Healthcare Conference 2025 in New York on Tuesday, June 4 at 11:40 a.m.
prnewswire.com
- 1 month ago
Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.
benzinga.com
- 1 month ago
GRAIL, Inc. (GRAL) Q1 2025 Earnings Call Transcript
GRAIL, Inc. (NASDAQ:GRAL ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Bob Ragusa - CEO Aaron Freidin - CFO Joshua Ofman - President Harpal Kumar - President, International Business and BioPharma Andy Partridge - Chief Commercial Officer Conference Call Participants Subbu Nabi - Guggenheim Partners Tejas Savant - Morgan Stanley Doug Schenkel - Wolfe Research Kyle Mikson - Canaccord Operator Good day, ladies and gentlemen. And welcome to the GRAIL First Quarter 2025 Earnings Call.
seekingalpha.com
- 1 month ago
GRAIL Reports First Quarter 2025 Financial Results
Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif. , May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025.
prnewswire.com
- 1 month ago
GRAIL and athenahealth Team Up to Offer Healthcare Providers Streamlined Ordering of GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test
MENLO PARK, Calif. , May 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with athenahealth, a leading provider of network-enabled software and services for healthcare practices and systems nationwide.
prnewswire.com
- 1 month ago
GRAIL to Announce First Quarter 2025 Financial Results
MENLO PARK, Calif. , April 29, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2025 following the close of market on Tuesday, May 13, 2025.
prnewswire.com
- 1 month ago
GRAIL to Present New Data on Galleri® and its Methylation Platform at American Association for Cancer Research (AACR) Annual Meeting
Real-World Data in 100,000 Patients Further Support the Galleri® Test's Ability to Simultaneously Screen for Multiple Cancers, as Well as its Accuracy of Cancer Signal of Origin Prediction to Support More Efficient Diagnostic Evaluations Data From GRAIL's ctDNA-based Targeted Methylation Assay Highlight Potential to Identify Robust Signals of Promoter Methylation MENLO PARK, Calif. , April 22, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present new data highlighting the latest real-world evidence with the Galleri® multi-cancer early detection (MCED) test and additional data from GRAIL's circulating tumor DNA (ctDNA)-based targeted methylation platform at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 25-30, 2025.
prnewswire.com
- 2 months ago
This Cancer Test Could Become Routine—and a Big Seller, Says Analyst
Grail stock will increase at least 20% over the next year, projects Canaccord's Kyle Gibson.
barrons.com
- 2 months ago
8. Profile
Summary
GRAIL, Inc. GRAL
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 1.64 B
Dividend Yield
0.00%
Description
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Contact
1525 O’Brien Drive, Menlo Park, CA, 94025
https://grail.com
IPO
Date
June 12, 2024
Employees
1000
Officers
Ms. Alison Highlander
Senior Vice President of Human Resources & Head of People Team
Ms. Trish Rowland
Vice President of Corporate Communications
Mr. Aaron Freidin
Chief Financial Officer
Mr. Paul Ciccolella
Senior Vice President of Research, Development & Operations
Sir Harpal S. Kumar M.A., M.B.A., MA, MBA, MEng
President of International Business & BioPharma
Dr. Satnam Alag Ph.D.
Senior Vice President of Software Engineering & Chief Security Officer
Mr. Abram Barth J.D., M.P.H.
General Counsel
Mr. Rodger Currie J.D.
Senior Vice President of Government Affairs
Mr. Robert P. Ragusa
Chief Executive Officer & Director
Dr. Joshua J. Ofman M.D., M.S.H.S
President